|
CA1296229C
|
|
Apparatus for dissolving a solidified mass in vivo
|
|
US5064862A
|
|
Anticonvulsant method and formulations
|
|
GB8918324D0
|
|
Dienophiles
|
|
GB8907365D0
|
|
Lipocortin peptides
|
|
US4994462A
|
|
Platelet aggregation inhibitory agents and intermediate therefor
|
|
WO8900696A1
|
|
Antenatal screening for down's syndrome
|
|
EP0351410A1
|
|
Complement-binding peptide
|
|
DK113288D0
|
|
Polypeptime competitor for immunoglobulin
|
|
US4833294A
|
|
Inductively coupled helium plasma torch
|
|
DK641987A
|
|
Survival activities
|
|
US5023108A
|
|
Aqueous dispersions of waxes and lipids for pharmaceutical coating
|
|
EP0319538A1
|
|
Modification of zeolites
|
|
US5180805A
|
|
Polypeptide competitor for immunoglobulin E
|
|
US4828764A
|
|
N-Fluoro-N-Perfluoromethyl sulfonamides
|
|
AU7329687A
|
|
Steroids useful as anti-cancer and anti-obesity agents
|
|
IL82588A
|
|
Androstan-17-one and androsten-17-one derivatives and pharmaceutical compositions containing the same
|
|
US4921790A
|
|
Tumor specific assay for CA125 ovarian cancer antigen
|
|
AU7178687A
|
|
Method for dissolving cholesterol calculus in methyl tertiary-butyl ether
|
|
US4814612A
|
|
Method and means for vaporizing liquids for detection or analysis
|
|
DK140387D0
|
|
Determination of haptens by immuno analysis methods
|
